Team
health

EORTC Bladder Cancer Recurrence and Progression Calculator

Non-muscle invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder malignancies. Clinicians need accurate prognostication to guide treatment intensity and surveillance protocols. This calculator applies the European Organisation for Research and Treatment of Cancer (EORTC) risk stratification model, incorporating six clinical parameters to estimate one- and five-year recurrence and progression probabilities, enabling individualised patient counselling and therapy selection.

Last updated:

Creators Małgorzata Koperska, MD
3,017 people find this calculator helpful

Understanding Non-Muscle Invasive Bladder Cancer

Non-muscle invasive bladder cancer remains confined to the mucosa or lamina propria, representing the majority of bladder malignancies at presentation. Prognosis varies substantially based on tumour characteristics and patient factors, necessitating a structured approach to risk assessment.

Key prognostic features include:

  • Tumour number and size: Solitary lesions generally carry lower recurrence risk than multiple tumours. Diameter exceeding 3 cm predicts more aggressive behaviour.
  • Histological grade: Low-grade tumours (G1) show substantially lower progression rates than high-grade lesions (G2–G3).
  • Stage: Muscularis propria invasion (T1) and carcinoma in situ (CIS) confer higher progression risk than superficial tumours (Ta).
  • Prior recurrence history: Patients with documented earlier recurrence demonstrate elevated lifetime recurrence probability.
  • Concomitant CIS: Presence of CIS at diagnosis substantially increases progression to muscle-invasive disease.

EORTC Risk Scoring Formula

The calculator computes separate point scores for recurrence and progression risk using a weighted system based on clinical trial data from over 2,500 patients with NMIBC. Each parameter contributes points to a cumulative risk score, which is then converted to probability estimates.

Recurrence Points = Number + Size + Prior Recurrence + Stage + CIS + Grade

Progression Points = Number + Size + Prior Recurrence + Stage + CIS + Grade

1-year Recurrence Risk (%) = f(Recurrence Points)

5-year Recurrence Risk (%) = f(Recurrence Points)

1-year Progression Risk (%) = f(Progression Points)

5-year Progression Risk (%) = f(Progression Points)

Where the function f() converts cumulative points into probability percentages using EORTC nomogram tables derived from multivariate logistic regression analysis.

  • Number — Quantity of tumours identified at transurethral resection (single vs. multiple)
  • Size — Maximum diameter of the largest lesion in millimetres
  • Prior Recurrence — History of tumour recurrence before the index resection (present or absent)
  • Stage — Depth of invasion: Ta (mucosa only), T1 (lamina propria), or CIS (flat high-grade lesion)
  • CIS — Concomitant carcinoma in situ identified at or around the primary tumour
  • Grade — WHO histological differentiation: G1 (low-grade) vs. G2–G3 (high-grade)

Clinical Application and Limitations

Accurate risk stratification requires careful interpretation of both calculator output and clinical context.

  1. Pathology review consistency — EORTC scores depend on accurate tumour grading and staging from the transurethral resection specimen. Re-review by experienced uropatologists may reclassify grade in 15–25% of cases, substantially altering risk category. Always verify pathology documentation before counselling patients.
  2. Risk category drift over time — The EORTC model predicts outcomes within 5 years of initial diagnosis. Recurrence-free patients beyond 5 years demonstrate different recurrence kinetics. Serial follow-up findings may shift a patient between low, intermediate, and high-risk groups, requiring reassessment of surveillance intensity.
  3. Individual variation around point estimates — Nomogram predictions represent average population outcomes; individual patient trajectories vary. A patient assigned 35% five-year recurrence risk still has a 65% recurrence-free probability. Confidence intervals and shared decision-making improve counselling quality beyond point estimates alone.
  4. Treatment impact not captured — The calculator predicts natural history recurrence and progression without accounting for intravesical therapy benefit. Bacillus Calmette–Guérin (BCG) or mitomycin C significantly reduce recurrence in high-risk disease, but this model assumes no adjuvant treatment.

Clinical Context and Surveillance Strategy

Risk stratification guides both intensity of initial intravesical therapy and duration of cystoscopic surveillance. The EORTC model categorises patients into three risk strata:

  • Low-risk NMIBC: Solitary Ta G1 tumours without CIS or prior recurrence. Standard management includes transurethral resection alone; routine intravesical chemotherapy offers marginal benefit. Surveillance cystoscopy at 3 months, then 12-monthly for 5 years.
  • Intermediate-risk NMIBC: Tumours not fitting low or high-risk definitions. Single-dose intravesical chemotherapy at resection reduces recurrence by 30–40%. Cystoscopy at 3 months and 6 months, then 6-monthly surveillance.
  • High-risk NMIBC: T1 grade, G3 grade, CIS, or multiple high-grade recurrent tumours. BCG induction course followed by maintenance therapy substantially reduces progression (50–60% of patients progress without treatment; BCG reduces this to 15–25%). Intense surveillance with upper tract imaging.

Progression to muscle-invasive disease necessitates radical cystoprostatectomy (males) or radical cystectomy (females) with urinary diversion. Discussion of this outcome before initiating surveillance is essential for informed consent.

Frequently Asked Questions

What is the difference between recurrence and progression in bladder cancer?

Recurrence refers to the reappearance of non-muscle invasive tumours in the bladder (same or different location) within the urothelium. Progression indicates advancement to muscle-invasive disease (stage T2 or higher) or metastatic spread. A patient may experience recurrence without progression, but progression almost always follows prior recurrence. The EORTC model predicts both trajectories independently because they require different management approaches.

Why does prior recurrence history increase risk scores?

Patients with documented earlier recurrence exhibit field defects—widespread urothelial abnormalities predisposing the entire bladder mucosa to malignant transformation. This biological phenomenon is independent of complete resection quality. Studies show recurrence-free intervals progressively shorten with each subsequent recurrence, suggesting clonal selection for more aggressive urothelial populations.

How reliable is the EORTC calculator for individual patient counselling?

The EORTC nomogram demonstrates strong discrimination (concordance index ~0.75) in large populations and has been externally validated across European cohorts. However, predictions are probabilistic averages; individual outcomes vary. Additionally, the original model predates modern imaging, molecular markers, and BCG resistance patterns. Use calculator results alongside clinical judgment, patient preferences, and discussion of both best-case and worst-case scenarios.

Does BCG therapy change the risk percentages predicted by this calculator?

No. The EORTC calculator predicts untreated natural history. BCG induction reduces five-year progression risk by approximately 50% in high-risk patients; maintenance therapy further improves outcomes but requires patient tolerance and bladder preservation goals. Discuss baseline calculator estimates as motivation for adhering to BCG treatment rather than surveillance alone.

What should prompt repeat risk assessment after initial diagnosis?

Repeat pathology review at initial resection (if high-grade disease suspected), findings at three-month repeat cystoscopy (residual disease, grade changes), and outcomes after intravesical therapy all may alter risk stratification. Additionally, cumulative recurrence patterns over two to three years provide real-world outcome data that may supersede initial nomogram estimates for individualising future surveillance.

Can this calculator predict the need for radical cystectomy?

The calculator estimates five-year progression probability but does not predict individual cystectomy candidacy. Progression risk interacts with patient age, renal function, comorbidities, and patient preference for bladder preservation. A 70-year-old with 40% progression risk and significant cardiovascular disease may opt for close surveillance rather than immediate cystectomy, whereas a fit 50-year-old with identical risk may choose surgery.

health
ACFT Calculator

More health calculators (see all)

RMR Calculator FIB-4 Calculator IIFYM Calculator Tinetti Calculator PaO2/FiO2 Ratio Calculator Lung Cancer Risk Calculator for Smokers BMI for Kids Calculator Tidal Volume Calculator